Vascular Surgery Journal Review: Carotid Revascularization Strategies

Understanding Carotid Artery Disease

• 🎯 Carotid artery disease management has evolved from aggressive surgical intervention to a more nuanced approach considering medical therapy, stenting, and newer techniques.
• 🔑 Key decisions in managing carotid stenosis hinge on patient symptoms (symptomatic vs. asymptomatic) and the degree of narrowing (high-grade >70%, moderate 50-69%, mild <50%).
• 🧠 Individual patient risk profiles, including comorbidities and life expectancy, are crucial for determining the best course of action.

Landmark Trials and Their Impact

• 💡 The North American Symptomatic Carotid Endarterectomy Trial (NASCET) established the benefit of carotid endarterectomy (CEA) for symptomatic patients with high-grade stenosis (>70%), showing a significant reduction in stroke risk compared to medical therapy alone.
• ⚠️ While CEA showed upfront risks, long-term benefits were substantial, with absolute risk reduction around 17% at 2 years for high-grade symptomatic stenosis.
• 📈 Advances in best medical management have improved outcomes, making intervention thresholds more selective, especially for moderate stenosis (50-69%).

Carotid Stenting vs. Endarterectomy (CREST Trial)

• ⚖️ The Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST) compared CEA to carotid artery stenting (CAS), finding similar long-term outcomes but different periprocedural risks.
• 📉 Stenting showed a higher incidence of stroke perioperatively, while CEA had a higher incidence of myocardial infarction (MI).
• 👴👵 Age played a role, with stenting performing better in younger patients and CEA in older patients, often attributed to vascular calcification and aortic arch anatomy.
• 🚀 Transcarotid Artery Revascularization (TCAR) emerged as a newer technique, potentially mitigating some risks associated with traditional trans-femoral stenting, especially concerning aortic arch manipulation and calcification.

Managing Asymptomatic Stenosis (ACST Trials)

• 📊 The Asymptomatic Carotid Surgery Trial (ACST) demonstrated that CEA benefits asymptomatic patients with >60% stenosis, offering a ~5% absolute risk reduction in stroke at 5 years, particularly pronounced in men and those under 75.
• 🤝 ACST-2 compared CAS to CEA in asymptomatic patients, finding both procedures safe with similar long-term outcomes, though stenting had a slightly higher risk of non-disabling stroke perioperatively.
• 🧐 Current practice leans towards aggressive medical management for asymptomatic patients, with intervention considered for stenosis >80%, especially if there are signs of plaque ulceration, embolization, or rapid progression.

Diagnostic Modalities and Clinical Scenarios

• 🔍 While duplex ultrasound is a primary screening tool, confirmatory studies like CTA or MRA are often necessary for accurate stenosis assessment and surgical planning, especially for high-grade or equivocal findings.
• 🩺 Diagnostic angiography still has a role as a tiebreaker or for immediate intervention, particularly in symptomatic patients, but carries its own stroke risk.
• 🚦 Clinical decisions are highly individualized, weighing trial data against patient-specific factors like symptoms, stenosis severity, anatomy, comorbidities, and patient preference to determine the optimal revascularization strategy.